I wonder if the tide is turning for Arixtra(fondapirinux) and whether this may have implications for the eventual market for m-enoxaparin.
I was surprised to learn that a well-run NH hospital where I have worked is phasing out Lovenox this month, and substituting Arixtra.
Here is a portion of the letter from the Pharmacy and Therapeutics committee: Formulary Change:
In the continued efforts to provide patients at XXXX Hospital with safe, effective and cost efficient medications, the Pharmacy and Therapeutics Committee approved the addition of Arixtra® (fondaparinux) to the hospital’s formulary in place of enoxaparin.
This decision was made based on provider requests, patient safety, drug information, once a day dosing of fondaparinux, reports in literature supporting the use of fondaparinux in the treatment or prophylaxis of thromboembolism in patients with heparin-induced thrombocytopenia (HIT), and cost savings for the organization.
Therefore, over the next several weeks the organization will be making the conversion from enoxaparin to fondaparinux. A complete conversion will be implemented no later than August 1, 2009.
I would be interested if there is other evidence from across the US that Arixtra is taking turf.
Aside from having to learn how to use a new drug, my concern as a MNTA holder is that if Arixtra is able to position itself with a significant market share just prior to generic enoxaparin being approved, it may pose a significant barrier to adoption of the generic (i.e. MNTA produced) drug.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.